Will GLP-1 drugs (Ozempic, etc.) become available over-the-counter before 2028?

GLP-1 drugs require careful dose titration, monitoring for side effects (pancreatitis, thyroid concerns), and medical supervision for appropriate patient selection. The FDA's OTC switch process is rigorous and typically requires years of post-marketing safety data. While Novo Nordisk and Eli Lilly have enormous commercial incentive for OTC access, the medical complexity and safety monitoring requirements make an OTC approval by 2028 extremely unlikely. The FDA has not even begun formal OTC review for any GLP-1 product.

Last updated: Mar 2, 2026

Resolves YES if the FDA approves any GLP-1 receptor agonist for over-the-counter sale (without prescription) before January 1, 2028. The approval must cover the injectable or oral form for weight management or diabetes.

Source: FDA Drug Approval Database / FDA Press Releases

Expected resolution: January 15, 2028